# Bipolar Disorder

Bipolar disorder requires longitudinal diagnostic assessment and phase-specific treatment. Prioritize recognition of past mania or hypomania in depressed patients, manage acute episodes with mood stabilizers or antipsychotics, and sustain relapse prevention through individualized maintenance medication, psychosocial care, and safety monitoring.

**Clinical question:** How should clinicians confirm bipolar disorder and select phase-specific acute and maintenance treatment?

Updated: 2026-08-21T01:32:09.050523+00:00

## What matters in practice
- Diagnosis depends on a comprehensive current mental-status assessment plus longitudinal history obtained from the patient and family; depressive disorders are a frequent source of misdiagnosis.[4]
- Acute mania and maintenance management require a mood stabilizer or antipsychotic, alone or in combination; antidepressant monotherapy is not indicated for bipolar disorder.[4]
- Quetiapine extended release is FDA-labeled for bipolar depressive episodes at 300 mg/day after a 4-day titration and for bipolar I maintenance adjunctive to lithium or divalproex at 400-800 mg/day.[2]
- Lamotrigine is FDA-indicated for maintenance treatment of bipolar I disorder after acute mood stabilization, but is not recommended for acute manic or mixed episodes and has not established efficacy for acute mood episodes.[3]

## Establish the longitudinal mood-episode diagnosis

Do not diagnose or exclude bipolar disorder from the current depressive presentation alone.

Diagnostic assessment should integrate the mental-status examination with a longitudinal account of mood episodes, including collateral history from family when available.[4] In patients presenting with depression, actively seek prior manic or hypomanic episodes because unipolar depressive disorders are a common diagnostic misclassification.[4]

Screening instruments can improve recognition but do not replace diagnostic assessment. The Mood Disorder Questionnaire is widely used; one tertiary mental-health study reported sensitivity of 66% (95% CI, 57%-73%) and specificity of 86%.[16] A positive screen should trigger a structured clinical history rather than establish the diagnosis.
- Clarify episode polarity, severity, frequency, interepisode symptoms, prior treatments and responses, functional consequences, and associated risk.[6]
- Assess substance use, medication adherence, potential relapse triggers, early warning signs, and self-management strategies before attributing nonresponse to pharmacologic failure.[6][15]
- Differentiate recurrent episodic mood change from affective instability associated with other conditions; this distinction has direct treatment implications.[20]

*High-yield diagnostic inputs and their practical use.[4][6][16]*

| Input | Clinical use |
| --- | --- |
| Current mental-status examination | Characterize present mood state, psychosis, behavioral activation, impairment, and immediate risk as part of the diagnostic assessment.[4] |
| Longitudinal patient and collateral history | Identify prior manic, hypomanic, depressive, or mixed episodes and establish illness course; include family input when available.[4] |
| Mood Disorder Questionnaire | Use as a case-finding aid, not a diagnostic test; reported sensitivity was 66% and specificity 86% in one tertiary setting.[16] |
| Treatment and relapse history | Review prior response, adherence, episode severity and frequency, triggers, and early warning signs to guide treatment selection and relapse planning.[6] |

## Match treatment to episode polarity

Acute treatment choice should be driven by mania, depression, mixed features, severity, and prior response.

For acute mania, mood stabilizers and antipsychotics are core therapies, used as monotherapy or in combination.[4] Antipsychotics are effective for acute mania, whereas their efficacy for depression varies by agent.[8] Lithium remains a first-line option for mania in many contemporary guidelines, either alone or in combination.[15]

For moderate or severe bipolar depression in a patient not receiving a bipolar medication, NICE-based guidance supports quetiapine monotherapy or fluoxetine combined with olanzapine.[6] Quetiapine and olanzapine-fluoxetine combination have evidence for bipolar depression in systematic review evidence.[21] Traditional antidepressants alone are not indicated in bipolar disorder.[4]

When a first-line antimanic agent at therapeutic dose has not produced sufficient response after 1-2 weeks, reassess dose optimization, adherence, and substance use before considering combination treatment.[15] This interval is guidance cited in a review of contemporary guideline recommendations rather than a patient-specific mandate.
- Choose treatment with the anticipated maintenance strategy in view; acute stabilization is only one component of recurrent-illness care.[5]
- For bipolar depression, monitor for emergent mania or hypomania and for worsening depressive symptoms during pharmacologic and psychological treatment.[6]
- Escalate care based on acute safety, behavioral disturbance, psychosis, inability to maintain self-care, and need for intensive monitoring; the supplied sources do not provide operational thresholds for site-of-care decisions.

### Quetiapine extended-release dosing in FDA labeling

For adults with bipolar depressive episodes, the extended-release quetiapine label specifies 50 mg/day on day 1, 100 mg/day on day 2, 200 mg/day on day 3, and 300 mg/day on day 4, followed by 300 mg/day.[2] For adult bipolar I maintenance adjunctive to lithium or divalproex, labeled dosing is 400-800 mg/day.[2]
- In a 3-week placebo-controlled bipolar mania study of extended-release quetiapine, commonly observed adverse reactions occurring at least twice the placebo rate included somnolence (50% vs 12%), dry mouth (34% vs 7%), dizziness (10% vs 4%), constipation (10% vs 4%), and weight gain (7% vs 3%).[2]
- The available FDA-label excerpt is from 2017; verify the current product-specific U.S. prescribing information before prescribing.[2]

*Phase-specific pharmacologic options supported by the supplied evidence.[2][3][4][6][8][15][21]*

| Clinical phase | Supported approach | Important limitation or tradeoff |
| --- | --- | --- |
| Acute mania | Use a mood stabilizer or antipsychotic as monotherapy or in combination; lithium is a first-line option in many guidelines.[4][15] | Before adding therapy after inadequate response, address dose, adherence, and substance use.[15] |
| Bipolar depression | Quetiapine monotherapy or olanzapine-fluoxetine combination are supported options in cited guidance and review evidence.[6][21] | Antidepressant monotherapy is not indicated; monitor for mood switching or clinical deterioration.[4][6] |
| Bipolar I maintenance | Consider ongoing medication after acute stabilization; quetiapine XR is labeled adjunctively with lithium or divalproex at 400-800 mg/day.[2] | Periodically reassess need for maintenance therapy.[2] |
| Lamotrigine use | Use for FDA-indicated maintenance treatment of bipolar I disorder to delay mood episodes after treatment of acute episodes with standard therapy.[3] | Do not use as treatment for acute manic or mixed episodes; acute mood-episode efficacy has not been established in the label.[3] |

## Treat relapse prevention as the central management objective

Maintenance planning should begin during acute stabilization and be revisited after every episode.

Bipolar disorder is recurrent; a cited review reports typical recurrence every 17-30 months, underscoring the need to reduce both manic and depressive relapse rather than merely terminate the index episode.[5] Long-term management should individualize medication, adjunctive psychosocial therapy, monitoring for treatment-emergent complications, and health behaviors including sleep hygiene, exercise, and stress management.[4]

Lithium and valproate are both recommended monotherapies for relapse prevention in the source trial background.[12] Lithium and quetiapine are described in a review of guideline evidence as agents with level 1 evidence for prevention of both manic and depressive episodes.[15] Selection should incorporate prior episode polarity, treatment response, adverse-effect burden, reproductive plans, comorbidity, and feasibility of monitoring.
- Discuss the expected benefits and risks of long-term treatment, relapse after dose reduction or discontinuation, and the need to monitor mood and medication effects.[6]
- Review pregnancy intentions before medication changes; teratogenic concerns require treatment review in people planning pregnancy.[5][6]
- Medication adverse effects may persist into maintenance and some clinically important toxicities emerge only with longer-term exposure; use agent-specific monitoring schedules.[5]
- Offer a bipolar-specific psychological intervention with an evidence-based manual, or a high-intensity intervention such as cognitive behavioral therapy, interpersonal therapy, or behavioral couples therapy when appropriate.[6]

*Maintenance decisions that should be explicitly revisited.[2][3][5][6]*

| Decision | Action |
| --- | --- |
| Need for ongoing therapy | Periodically reassess the need for maintenance treatment while accounting for recurrent illness course and prior relapse burden.[2][5] |
| Medication tolerability | Monitor medication-specific adverse effects and toxicity; some adverse effects persist and some become evident only with long-term treatment.[5] |
| Stopping or reducing therapy | Discuss relapse risk, expected benefits and harms, and monitor mood closely when treatment changes are contemplated.[6] |
| Psychosocial relapse prevention | Use bipolar-specific or high-intensity psychological interventions alongside medication when clinically appropriate.[6] |

## Avoid polarity-treatment mismatches

The highest-value prescribing error is using an agent outside its evidence-supported role for the current phase.

Lamotrigine is indicated for bipolar I maintenance to delay mood episodes in patients treated for acute mood episodes with standard therapy.[3] Its label specifically states that treatment of acute manic or mixed episodes is not recommended and that effectiveness for acute mood episodes has not been established.[3] Do not infer acute antimanic efficacy from its maintenance indication.

Quetiapine has phase-specific labeled dosing and clinically meaningful sedating and metabolic adverse effects in trial data.[2] Somnolence, dry mouth, dizziness, constipation, and weight gain should influence dose titration, counseling, fall-risk assessment, and follow-up planning.[2]
- Do not treat a positive bipolar screening result as confirmation; obtain a longitudinal episode history and collateral information when possible.[4][16]
- Do not use traditional antidepressants alone for bipolar disorder.[4]
- Do not assume all antipsychotics have equivalent efficacy for bipolar depression; available evidence describes variable antidepressant efficacy across agents.[8]

*Common treatment errors and corrective actions.[2][3][4][8][16]*

| Potential error | Corrective action |
| --- | --- |
| Labeling recurrent depression as unipolar without probing for prior activation | Obtain longitudinal patient and family history and use screening tools only as adjuncts to diagnostic assessment.[4][16] |
| Using antidepressant monotherapy | Use a bipolar-specific pharmacologic strategy; traditional antidepressants alone are not indicated.[4] |
| Using lamotrigine for acute mania | Select an antimanic treatment instead; lamotrigine is not recommended for acute manic or mixed episodes.[3] |
| Ignoring quetiapine adverse effects during titration | Anticipate somnolence, dry mouth, dizziness, constipation, and weight gain, and adjust monitoring and counseling accordingly.[2] |

## Common questions

### Should the Mood Disorder Questionnaire be used to diagnose bipolar disorder?

No. It may improve case finding, but diagnosis requires comprehensive clinical assessment, current mental-status examination, and longitudinal patient and collateral history. One cited study reported sensitivity of 66% and specificity of 86%.[4][16]

### Is lamotrigine appropriate for acute mania?

No. FDA labeling states that lamotrigine is not recommended for acute manic or mixed episodes and that acute mood-episode effectiveness has not been established. Its bipolar indication is maintenance treatment of bipolar I disorder after acute stabilization.[3]

### What is the labeled quetiapine extended-release dose for adult bipolar depression?

The supplied FDA label specifies 50 mg/day on day 1, 100 mg/day on day 2, 200 mg/day on day 3, and 300 mg/day on day 4, then 300 mg/day.[2]

### When should combination treatment be considered for mania?

A review of guideline recommendations suggests considering combination treatment after insufficient response following 1-2 weeks at therapeutic doses of a first-line antimanic agent, after dose optimization and assessment of adherence and substance use.[15]

## References
1. 2970592 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf
2. quetiapine fumarate extended-release tablets — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/090482Orig1s000lbl.pdf
3. These highlights do not include all the information needed to use LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS and LAMOTRIGINE TABLETS FOR ORAL SUSPENSION. <br/> <br/> LAMOTRIGINE tablets, for oral use <br/> LAMOTRIGINE tablets for oral suspension <br/> Initial U.S. Approval: 1994 — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/15d801a0-f0a5-40c1-bc88-d5ba9a02c696/spl-doc
4. Bipolar disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/488
5. Maintaining mood stability in bipolar disorder — mentalhealth.bmj.com — https://mentalhealth.bmj.com/content/18/1/1.full.pdf
6. Assessment and management of bipolar disorder — www.bmj.com — https://www.bmj.com/bmj/section-pdf/765723?path=%2Fbmj%2F349%2F7976%2FPractice.full.pdf
7. Drug treatments for bipolar disorder: 1 - Acute manic or depressive | Drug and Therapeutics Bulletin — dtb.bmj.com — https://dtb.bmj.com/content/43/4/28
8. Treatment of bipolar disorder — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60857-0/abstract
9. Drug treatments for bipolar disorder: 2 - Maintenance, prevention and special situations | Drug and Therapeutics Bulletin — dtb.bmj.com — https://dtb.bmj.com/content/43/5/33
10. Bipolar disorder — www.bmj.com — https://www.bmj.com/bmj/section-pdf/187715?path=
11. Bipolar disorders: an update on critical aspects — www.thelancet.com — https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00304-1/fulltext
12. Lithium plus valproate combination therapy versus ... — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61828-6/fulltext
13. The Emerging Neurobiology of Bipolar Disorder — www.cell.com — https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(17)30212-6
14. From theory to practice: Revealing the real-world impact of ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)13794-2
15. Existing and emerging pharmacological approaches to the treatment of mania: A critical overview — www.nature.com — https://www.nature.com/articles/s41398-022-01928-8
16. Screening for bipolar disorder in a tertiary mental health ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666915321001414
17. Review Differential diagnosis of bipolar disorder and major ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0165032714700047
18. Presentation, Clinical Course, and Diagnostic Assessment of ... — academic.oup.com — https://academic.oup.com/book/24609/chapter/187895759
19. Screening for bipolar disorder in a Spanish sample of outpatients with current major depressive episode — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165032708002814
20. Differential diagnosis of bipolar affective disorder type II and borderline personality disorder: analysis of the affective dimension — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0010440X12000454
21. Treatment of bipolar disorder: a systematic review of available ... — academic.oup.com — https://academic.oup.com/ijnp/article/11/7/999/787005
22. a CINP Task Force report based on a review of evidence — academic.oup.com — https://academic.oup.com/ijnp/article/10/Supplement_1/S1/855835
23. Pharmacological Augmentation in Unipolar Depression — academic.oup.com — https://academic.oup.com/ijnp/article/23/9/587/5836840
24. 12 APPENDICES — www.nice.org.uk — https://www.nice.org.uk/guidance/cg185/documents/bipolar-disorder-update-draft-full-guideline-appendices-1102

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.